newsfilter
← Latest News
GlobeNewswire·

INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives

Boca Raton, FL, Jan. 27, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:INMB), a clinical-stage inflammation and immunology company, presents the following letter to investors from David Moss, CEO: Dear Fellow